title: Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
abstract: Endocrine therapies that profoundly decrease estrogen levels potentially have a detrimental effect on the cardiovascular system. This study evaluated the effect on lipid metabolism of one such agent, the new generation aromatase inhibitor anastrozole, compared with tamoxifen, when used as adjuvant treatment in postmenopausal Japanese women with early breast cancer. All patients had completed primary surgery and were randomized to anastrozole 1 mg once daily (n=22) or tamoxifen 20 mg once daily (n=22). Anastrozole significantly reduced levels of triglycerides and remnant-like particle cholesterol, whereas tamoxifen significantly increased these. Activity of lipoprotein lipase and levels of high-density lipoprotein cholesterol significantly increased after anastrozole treatment. In contrast, activity of hepatic triglyceride lipase, also a key enzyme of triglyceride metabolism, significantly decreased following treatment with tamoxifen. We thus conclude that in our study anastrozole had a beneficial effect on lipid profiles of postmenopausal women with early breast cancer after 12 weeks of treatment.
authors.affiliation: Department of Internal Medicine I, National Defense Medical College, Tokorozawa, Japan. grd1507@gr.ndmc.ac.jp
authors.forename: Shojiro
authors.initials: S
authors.lastname: Sawada
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Sato
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kusuhara
authors.forename: Makoto
authors.initials: M
authors.lastname: Ayaori
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yonemura
authors.forename: Kuniyoshi
authors.initials: K
authors.lastname: Tamaki
authors.forename: Hoshio
authors.initials: H
authors.lastname: Hiraide
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Mochizuki
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Ohsuzu
mesh_terms: D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007564:Japan; D008055:Lipids / Q000097:blood*; D008071:Lipoprotein Lipase / Q000097:blood; D008875:Middle Aged; D009570:Nitriles / Q000494:pharmacology* / Q000627:therapeutic use; D017698:Postmenopause; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D008055:Lipids; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D004958:Estradiol; D008071:Lipoprotein Lipase